-
2023-510307-22-00
1
2021-09-24
Advanced head and neck cancer
-
2024-516554-22-00
4
2021-03-29
Locally-advanced stage II-III rectal cancer
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)
-
2023-507475-21-00
10
2021-01-18
Lung Cancer, Non-Small Cell
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2024-514733-38-00
5
2020-11-03
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2022-502746-27-00
5
2020-08-21
Endometrial Cancer
-
2023-508962-14-00
5
2020-06-18
Relapsed/Refractory Multiple Myeloma
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2022-502354-14-00
5
2019-10-28
Completely resected Stage IIb/c melanoma
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2023-505495-30-00
5
2019-02-01
Immunoglobulin A Nephropathy (IgAN)
-
2022-502798-40-00
5
2017-07-31
Patients with resected colon carcinoma
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-516106-31-00
10
2017-06-16
Early stage colorectal cancer
-
2023-510298-33-00
4
2016-11-29
Prostate Cancer
-
2024-511348-25-00
10
2015-12-11
Myelodysplastic syndromes (MDS)
-
2023-510453-41-00
5
2015-10-26
Castration resistant prostate cancer patients metastatic to bone.
-
2023-505096-68-00
4
2025-01-14
Preclinical Alzheimer’s Disease
-
2023-505433-27-00
5
2024-08-13
Atopic Dermatitis